Blood pressure management in the kidney transplant recipient.
Hypertension is extremely common after kidney transplantation. It has been observed in up to 80% to 90% of patients. The etiologies are multifactorial but, in large part, rest with the native kidneys, concomitant immunosuppressant drugs, and behavioral factors that promote the development of higher levels of blood pressure, including obesity, salt intake, smoking, and alcohol consumption. There is a direct relationship between kidney allograft failure and level of systolic blood pressure during follow-up. Patients with a systolic blood pressure greater than 180 mmHg have 2-fold greater risk of loss of graft function compared with patients with systolics of less than 140 mmHg. A similar pattern exists for diastolic blood pressure. Some investigators have also demonstrated that higher levels of blood pressure also correlate with an increased risk of acute graft rejection, particularly in African Americans. What is not known is whether more effective control of arterial pressure in the transplant patient will reduce the likelihood of graft loss and improve survival. No prospective outcome trials have ever been performed. However, it is likely, given the marked success of better control of blood pressure in nontransplant patients in reducing cardiovascular death and the rate of progression of kidney disease, that similar benefits will be appreciated in the transplant patient. Given the greater cardiovascular burden in the kidney transplant recipient because of the presence, in many cases, of diabetes and hypertension, perhaps even more risk reduction may be realized with incremental reductions in blood pressure. Preferred treatment strategies for lowering blood pressure depends on the mechanism of action and medical comorbidity. Drugs that block the renin-angiotensin system should be preferentially considered because they may have similar advantages in delaying progressive loss of allograft function, much in the same way they have proven benefits in protecting native kidney function. Treating blood pressure in the kidney transplant recipient is a complicated process because patients are already on multiple medications and many will need 3 to 5 antihypertensive drugs to achieve optimal control of blood pressure, which should preferably be below 130/80 mmHg.
Weir
Matthew R
MR
Division of Nephrology, University of Maryland School of Medicine, 22 South Greene Street, Suite N3W143, Baltimore, MD 21201, USA. mweir@medicine.umaryland.edu
D001794:Blood Pressure; D006706:Homeostasis; D006801:Humans; D006973:Hypertension / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology*; D006977:Hypertension, Renal / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007668:Kidney / Q000503:physiopathology; D016030:Kidney Transplantation / Q000009:adverse effects / Q000502:physiology
D007166:Immunosuppressive Agents